PFE Phase 3 readout: a positive outcome, -1.9%

On February 18, 2026, talazoparib plus enzalutamide — PFIZER (Prostate Cancer) reached its Phase 3 readout. The result was a positive outcome, and the stock moved -1.9% in the window around the event. It had already run +9.1% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.